Sho Uehara

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study).

C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study).

Journal: International urology and nephrology

Published: July 14, 2026

Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04).

Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04).

Journal: Japanese journal of clinical oncology

Published: January 02, 2026

Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.

Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.

Journal: The Prostate

Published: December 25, 2025

Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).

Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: December 16, 2025

Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis.

Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis.

Journal: Japanese journal of clinical oncology

Published: November 19, 2025

Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.

Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: October 01, 2025

Impact of Impaired Renal Function on the Efficacy and Safety of Enfortumab Vedotin Monotherapy in a Multicenter Real-World Cohort of Patients With Metastatic Urothelial Cancer: YUSHIMA Study.

Impact of Impaired Renal Function on the Efficacy and Safety of Enfortumab Vedotin Monotherapy in a Multicenter Real-World Cohort of Patients With Metastatic Urothelial Cancer: YUSHIMA Study.

Journal: Clinical genitourinary cancer

Published: July 29, 2025

Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).

Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 02, 2025

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol.

Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR) protocol.

Journal: BMJ open

Published: March 25, 2025

Real-World Outcomes of First-Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study).

Real-World Outcomes of First-Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study).

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 06, 2025

Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study).

Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study).

Journal: International journal of clinical oncology

Published: December 13, 2024

Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA Study).

Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA Study).

Journal: Clinical genitourinary cancer

Published: October 21, 2024

Showing 1-12 of 64

Last Updated: 09/26/2026